Our center is based at King’s College Hospital in London. The clinic receives referrals from all over the world, and acts as a tertiary referral centre for patients from the South East. In a typical year we will see about 200 new patients and fill 400 follow-up slots making this one of the busiest MND clinics in the world.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.